Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment.
Authors
Pedro Cabrales
UCSD, La Jolla, CA
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Modulating Innate Immunity
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 156)
DOI
10.1200/JCO.2019.37.8_suppl.156
Abstract #
156
Poster Bd #
H1
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.
First Author: Liron Zisman
Poster
2017 ASCO Annual Meeting
Chimeric antigen receptor (CAR) T cells genetically engineered to deliver IL-12 to the tumor microenvironment in ovarian cancer.
First Author: Oladapo O. Yeku
Poster
2024 ASCO Breakthrough
Therapeutically targeting the CALR/CD47 pathway in MPN to reactivate natural immunosurveillance mechanisms within the body to enhance treatment outcomes.
First Author: Ciro Roberto Rinaldi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Effect of sitravatinib combined with PD-1 blockade on cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma.
First Author: Ashten Omstead